{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T12:44:33Z","timestamp":1725972273202},"reference-count":31,"publisher":"Japanese Society of Hypertension","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2003]]},"DOI":"10.1291\/hypres.26.875","type":"journal-article","created":{"date-parts":[[2004,6,16]],"date-time":"2004-06-16T06:03:25Z","timestamp":1087365805000},"page":"875-880","source":"Crossref","is-referenced-by-count":21,"title":["Differing Anti-Proteinuric Action of Candesartan and Losartan in Chronic Renal Disease"],"prefix":"10.1291","volume":"26","author":[{"given":"Hiroto","family":"MATSUDA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"HAYASHI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"HOMMA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"YOSHIOKA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"KANDA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"TAKAMATSU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"TATEMATSU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"WAKINO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"SARUTA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"119","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Anderson S, Rennke HG, Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest<\/I> 1986; 77<\/B>: 1993-2000.","DOI":"10.1172\/JCI112528"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Taguma Y, Kitamoto Y, Futaki G, et al<\/I>: Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med<\/I> 1985; 313<\/B>: 1617-1620.","DOI":"10.1056\/NEJM198512263132601"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med<\/I> 1993; 326<\/B>: 1456-1462.","DOI":"10.1056\/NEJM199311113292004"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, AIPRI Study Group: Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med<\/I> 1996; 334<\/B>: 939-945.","DOI":"10.1056\/NEJM199604113341502"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Brenner BM, Cooper ME, de Zeeuw D, et al<\/I>: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med<\/I> 2001; 345<\/B>: 861-869.","DOI":"10.1056\/NEJMoa011161"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Lewis EJ, Hunsicker LG, Clarke WR, et al<\/I>, Collaborative Study Group: Renoprotective effect of the angiotensin-receptor blocker irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med<\/I> 2001; 345<\/B>: 851-860.","DOI":"10.1056\/NEJMoa011303"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Fabiani ME, Dinh DT, Nassis L, Casley DJ, Johnston CI: In vivo<\/I> inhibition of angiotensin receptors in the rat kidney by candesartan cilexetil: a comparison with losartan. Am J Hypertens<\/I> 2000; 13<\/B>: 1005-1013.","DOI":"10.1016\/S0895-7061(00)00286-7"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ojima M, Inada Y, Shibouta Y, et al<\/I>: Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor. Eur J Pharmacol<\/I> 1997; 319<\/B>: 137-146.","DOI":"10.1016\/S0014-2999(96)00837-0"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Hansson L: The relationship between dose and antihypertensive effect for different AT1-receptor blockers. Blood Press<\/I> 2001; 10<\/B> (Suppl 3): 33-39.","DOI":"10.1080\/08037050152518348"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Liu Y-H, Yang X-P, Sharov VG, et al<\/I>: Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in rats with heart failure: role of kinins and angiotensin II type 2 receptors. J Clin Invest<\/I> 1997; 99<\/B>: 1926-1935.","DOI":"10.1172\/JCI119360"},{"key":"11","doi-asserted-by":"crossref","unstructured":"12. Siragy HM, Jaffa AA, Margolius HS, Carey RM: Renin-angiotensin system modulates renal bradykinin production. Am J Physiol<\/I> 1996; 271<\/B>: R1090-R1095.","DOI":"10.1152\/ajpregu.1996.271.4.R1090"},{"key":"12","doi-asserted-by":"crossref","unstructured":"13. Kon V, Fogo A, Ichikawa I: Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int<\/I> 1993; 44<\/B>: 545-550.","DOI":"10.1038\/ki.1993.279"},{"key":"13","doi-asserted-by":"crossref","unstructured":"14. Matsuda H, Hayashi K, Arakawa K, et al<\/I>: Zonal heterogeneity in action of angiotensin-converting enzyme inhibitor on renal microcirculation: role of intrarenal bradykinin. J Am Soc Nephrol<\/I> 1999; 10<\/B>: 2272-2282.","DOI":"10.1681\/ASN.V10112272"},{"key":"14","doi-asserted-by":"crossref","unstructured":"15. Ohta K, Araki N, Shibata M, et al<\/I>: A novel in vivo<\/I> assay system for consecutive measurement of brain nitric oxide production combined with the microdialysis technique. Neurosci Lett<\/I> 1994; 176<\/B>: 165-168.","DOI":"10.1016\/0304-3940(94)90073-6"},{"key":"15","doi-asserted-by":"publisher","unstructured":"16. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet<\/I> 1996; 349<\/B>: 1857-1863.","DOI":"10.1016\/S0140-6736(96)11445-8"},{"key":"16","doi-asserted-by":"crossref","unstructured":"17. Wright JT Jr, Agodoa L, Contreras G, et al<\/I>: African American Study of Kidney Disease and Hypertension Study Group: successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med<\/I> 2002; 162<\/B>: 1636-1643.","DOI":"10.1001\/archinte.162.14.1636"},{"key":"17","doi-asserted-by":"crossref","unstructured":"18. Kuriyama S, Tomonari H, Tokudome G, et al<\/I>: Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy. Hypertens Res<\/I> 2003; 25<\/B>: 849-855.","DOI":"10.1291\/hypres.25.849"},{"key":"18","doi-asserted-by":"crossref","unstructured":"19. Gradman AH: AT1<\/sub>-receptor blockers: differences that matter. J Hum Hypertens<\/I> 2002; 16<\/B>: S9-S16.","DOI":"10.1038\/sj.jhh.1001434"},{"key":"19","doi-asserted-by":"crossref","unstructured":"20. Unger T: Pharmacology of AT1-receptor blockers. Blood Press<\/I> 2001; 10<\/B> (Suppl 3): 5-10.","DOI":"10.1080\/08037050152518302"},{"key":"20","doi-asserted-by":"crossref","unstructured":"21. Carey RM, Jin X, Wang Z, Siragy HM: Nitric oxide: a physiological mediator of the type 2 (AT2) angiotensin receptor. Acta Physiol Scand<\/I> 2000; 168<\/B>: 65-71.","DOI":"10.1046\/j.1365-201x.2000.00660.x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"22. Lacourciere Y, Asmar R: A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study: Candesartan\/Losartan study investigators. Am J Hypertens<\/I> 1999; 12<\/B>: 1181-1187.","DOI":"10.1016\/S0895-7061(99)00142-9"},{"key":"22","doi-asserted-by":"crossref","unstructured":"23. Sato A, Suzuki Y, Shibata H, Saruta T: Plasma aldosterone concentrations are not related to the degree of angiotensin-converting enzyme inhibition in essential hypertensive patients. Hypertens Res<\/I> 2000; 23<\/B>: 25-31.","DOI":"10.1291\/hypres.23.25"},{"key":"23","doi-asserted-by":"crossref","unstructured":"24. Sosa-Canache B, Cierco M, Gutierrez CI, Israel A: Role of bradykinin and nitric oxide in the AT2 receptor-mediated hypotension. J Hum Hypertens<\/I> 2000; 14<\/B>: S40-S46.","DOI":"10.1038\/sj.jhh.1000986"},{"key":"24","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1161\/01.HYP.35.5.1074","volume":"35","year":"2000","unstructured":"25. Siragy HM, de Gasparo M, Carey RM: Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats. Hypertension<\/I> 2000; 35<\/B>: 1074-1077.","journal-title":"Hypertension","ISSN":"http:\/\/id.crossref.org\/issn\/0194-911X","issn-type":"print"},{"key":"25","doi-asserted-by":"crossref","unstructured":"26. Weir MR, Henrich WL: Theoretical basis and clinical evidence for differential effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 blockers. Curr Opin Nephrol Hypertens<\/I> 2000; 9<\/B>: 403-411.","DOI":"10.1097\/00041552-200007000-00012"},{"key":"26","doi-asserted-by":"publisher","unstructured":"27. Kalinowski L, Matys T, Chabielska E, Buczko W, Malinski T: Angiotensin II AT1<\/SUB> receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension<\/I> 2002; 40<\/B>: 521-527.","DOI":"10.1161\/01.HYP.0000034745.98129.EC"},{"key":"27","doi-asserted-by":"crossref","unstructured":"28. Adler L, Mathew R, Futterweit S, Frank R, Gauthier BG, Kashtan CE, Trachtman H: Angiotensin converting enzyme inhibitor therapy in children with Alport syndrome: effect on urinary albumin, TGF-β, and nitrite excretion. BMC Nephrol<\/I> 2002; 3<\/B>: 2.","DOI":"10.1186\/1471-2369-3-2"},{"key":"28","doi-asserted-by":"crossref","unstructured":"29. Rahma M, Kimura S, Yoneyama H, et al<\/I>: Effects of furosemide on the tubular reabsorption of nitrates in anesthetized dogs. Eur J Pharmacol<\/I> 2001; 428<\/B>: 113-119.","DOI":"10.1016\/S0014-2999(01)01357-7"},{"key":"29","doi-asserted-by":"crossref","unstructured":"30. Kang DH, Nakagawa T, Feng L, Johnson RJ: Nitric oxide modulates vascular disease in the remnant kidney model. Am J Pathol<\/I> 2002; 161<\/B>: 239-248.","DOI":"10.1016\/S0002-9440(10)64175-2"},{"key":"30","doi-asserted-by":"crossref","unstructured":"31. Rangan GK, Wang Y, Harris DC: Pharmacologic modulators of nitric oxide exacerbate tubulointerstitial inflammation in proteinuric rats. J Am Soc Nephrol<\/I> 2001; 12<\/B>: 1696-1705.","DOI":"10.1681\/ASN.V1281696"},{"key":"31","doi-asserted-by":"crossref","unstructured":"32. Edwards RM: Response of isolated renal arterioles to acetylcholine, dopamine, and bradykinin. Am J Physiol<\/I> 1985; 248<\/B>: F183-F189.","DOI":"10.1152\/ajprenal.1985.248.2.F183"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T10:10:27Z","timestamp":1624443027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/hypres\/26\/11\/26_11_875\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2003]]}},"URL":"https:\/\/doi.org\/10.1291\/hypres.26.875","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003]]}}}